Background & Aims: The rate of new or missed colorectal cancer (CRC) after colonoscopy
and their risk factors in usual practice are unknown. Our objective was to evaluate the rate …

Background & Aims The medical management of ulcerative colitis (UC) has improved through
the development of new therapies and novel approaches that optimize existing drugs. …

Background. Inflammatory bowel disease (IBD) patients are not routinely screened for
depression and anxiety despite knowledge of an increased prevalence in people with chronic …

Background Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier
phase 2 induction study, etrolizumab significantly improved clinical remission compared …

Background The efficacy of vedolizumab, an α 4 β 7 integrin antibody, in Crohn's disease is
unknown. Methods In an integrated study with separate induction and maintenance trials, we …

Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous
phase 2 induction study, etrolizumab significantly improved clinical remission versus …

Background Conventional management of Crohn's disease features incremental use of
therapies. However, early combined immunosuppression (ECI), with a TNF antagonist and …

Background: Patients with immune-mediated diseases on immunosuppressive therapies have
more infectious episodes than healthy individuals, yet vaccination practices by physicians …

Background Fistulas occur in about 25% of patients with Crohn’s disease (CD) and can be
difficult to treat. The aim of this consensus was to provide guidance for the management of …

The aim of this study was to determine if body mass index (BMI) was an independent
predictor of response to antiviral treatment in patients with chronic hepatitis C. A retrospective …